Clinical Trials Browser

Advanced Melanoma

NCT00539591 2025-12-23

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Phase 2 Active not recruiting

29 enrolled 28 charts

Dermatologic

Melanoma

NCT05512481 2025-03-03

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Phase 2 Recruiting

60 enrolled

Dermatologic

Melanoma

NCT05827770 2023-04-25

The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma

Phase 2 Unknown

20 enrolled

Dermatologic

Melanoma

NCT00602576 2022-06-14

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Phase 2 Completed

169 enrolled 10 charts

Dermatologic

Melanoma

NCT04884997 2021-05-13

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

Phase 2 Unknown

90 enrolled

Dermatologic

Melanoma

NCT01328535 2020-10-22

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Completed

25 enrolled 8 charts

Dermatologic

Melanoma

NCT00505635 2020-09-24

Biochemotherapy With Temozolomide for Metastatic Melanoma

Phase 2 Terminated

5 enrolled 5 charts

Dermatologic

Melanoma

NCT00525031 2020-09-23

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Phase 2 Completed

55 enrolled 7 charts

Dermatologic

Melanoma

NCT04397770 2020-05-21

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Phase 2 Unknown

40 enrolled

Dermatologic

Melanoma

NCT01704287 2020-05-18

KEYNOTE 002

Phase 2 Completed

540 enrolled 20 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT00804908 2018-06-06

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Phase 2 Completed

346 enrolled 15 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00626405 2018-05-01

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

95 enrolled 8 charts

Dermatologic

Melanoma

NCT00521001 2017-08-14

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Phase 2 Completed

49 enrolled 8 charts

Dermatologic

Melanoma

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

120 enrolled 8 charts

Dermatologic

Uveal Melanoma

NCT00831545 2017-05-09

Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)

Phase 2 Completed

162 enrolled

BreastDermatologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00588341 2016-02-01

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

Phase 2 Completed

24 enrolled 4 charts

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT00673361 2016-01-13

Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma

Phase 2 Terminated

9 enrolled 3 charts

Dermatologic

Melanoma

NCT00885534 2015-05-06

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Phase 2 Completed

7 enrolled 6 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00338130 2014-08-13

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Phase 2 Completed

239 enrolled

Dermatologic

Melanoma

NCT01217398 2013-08-26

Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Unknown

35 enrolled

Dermatologic

Uveal Melanoma

NCT00568048 2013-04-10

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Completed

62 enrolled

Dermatologic

Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Completed

Dermatologic

Uveal Melanoma, Melanoma

NCT00072163 2013-01-17

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

Phase 2 Completed

50 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT00104988 2012-08-22

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Completed

64 enrolled

Dermatologic

Melanoma

NCT00004106 2012-06-06

Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Phase 2 Terminated

29 enrolled

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01048554 2012-04-19

MEL0107

Phase 2 Completed

34 enrolled

Dermatologic

Melanoma

NCT00991250 2010-02-05

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Phase 2 Unknown

140 enrolled

Dermatologic

Melanoma

NCT00383851 2007-12-06

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

Phase 2 Unknown

60 enrolled

Dermatologic

Melanoma

Clinical Trials

A Phase II Trial of LM103 in Advanced Melanoma

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Biochemotherapy With Temozolomide for Metastatic Melanoma

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

KEYNOTE 002

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

MEL0107

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma